Molecular Markers in Lung Cancer Pt 5: Dr. David Spigel on Incorporating Targets into Clinical Trials (audio)
05/10/12 • 24 min
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the benefits and challenges of conducting trials that include patient subgroups based on molecular markers.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the benefits and challenges of conducting trials that include patient subgroups based on molecular markers.
Previous Episode
Molecular Markers in Lung Cancer Pt 4: Broadening Use of Markers in Practice -- Panel Discussion (audio)
Panel discussion with 4 expert thought leaders in lung cancer about how we might best approach testing clinically relevant molecular targets in lung cancer patients.
Next Episode
Molecular Markers in Lung Cancer Pt 6: Dr. Glen Goss on Incorporating Markers Across a Health Care System (audio)
Dr. Glen Goss, University of Ottawa and NCI-Canada Lung Cancer Committee chair, discusses the potential and limitations of integrating molecular marker studies in advanced non-small cell lung cancer patients across a health care system.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/gracecast-lung-cancer-audio-126564/molecular-markers-in-lung-cancer-pt-5-dr-david-spigel-on-incorporating-6326778"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to molecular markers in lung cancer pt 5: dr. david spigel on incorporating targets into clinical trials (audio) on goodpods" style="width: 225px" /> </a>
Copy